Introduction
Immunoassays for hepatitis B surface antigen (HBsAg)' and hepatitis B e antigen (HBeAg) are unable to detect viral associated antigens at concentrations at the limit of infectivity; only a few viruses per milliliter. Filter hybridization assays for hepatitis B virus DNA (HBV DNA) can only detect 0. to I pg (2,500 to 25,000 viruses). While some HBsAg+ patients may not be actively producing virus and are not infectious, currently available assays are unable to distinguish these individuals from patients who have low levels of viral replication.
Prudent medical management must consider all HBsAg positive patients as infectious.
Recently, the polymerase chain reaction (PCR) for detecting DNA and RNA has allowed analysis of extremely small quantities of nucleic acid for the presence of sequences of interest (1, 2) . A difficulty with employing PCR methodology to detect HBV DNA sequences is that sera contain inhibitors of DNA polymerase. This has necessitated the extraction and purification of nucleic acid before performing PCR (3, 4) . Purification of nucleic acid is not totally efficient, often resulting in loss of nucleic acid sequences of interest.
We now describe a direct method of detecting serum HBV DNA by polymerase chain reaction. Less than 10 viruses can be identified. Furthermore, DNA can be directly sequenced from the amplified viral DNA. Using this method in two cases of acute self-limited hepatitis, surface antigenemia was found to precede viremia.
Methods

Sera and cells
HBsAg positive, HBV DNA positive sera were obtained from a variety of patients with chronic HBV infection. Sera were obtained from healthy blood donors at the Boston Beth Israel Hospital blood bank and the Sacramento Medical Foundation who had normal alanine aminotransferase (ALT), and no serological markers for HIV, HBV, and syphilis. The Sacramento Medical Foundation collected and saved plasma from volunteer HBsAg+ blood donors. Through Abbott Laboratories, we obtained serial plasma samples from two plasmaphoresis donors who became HBsAg positive. These patients were frequently plasmaphoresed during the course oftheir acute self-limited hepatitis B infection. All sera and plasma were stored at -20'C.
Serological assays
HBsAg, anti-HBc IgM, and HBeAg were tested by commercial enzyme-linked immunoassays (Abbott Laboratories, North Chicago, IL). Pre-S2 antigen was assayed by a radioimmunoassay in which 200 y1 sera were incubated overnight at 20'C with beads from the Auszyme assay (Abbott Laboratories). After washing, '251I-labeled anti-pre-S2 monoclonal antibodies were incubated with the beads for 2 h at 40°C, washed, then counted. A signal to noise ratio (S/N) of greater than 3.0 was considered positive.
Serum HBV DNA was detected both by the Abbott Genostics hepatitis B viral DNA assay ( 11) and by dot blot hybridization (5 IN) . Monoclonal IgG or IgM molecules were covalently coupled to these microparticles using l-ethyl-3-3 (dimethylaminopropyl) carbodiimide chemistry (7, 8) . After coupling, microparticles were centrifuged for 15 min at 17,000 rpm (JA19 rotor); supernatant decanted; and microparticles resuspended at 1.6% vol/vol in 150 mM Tris, pH 8.0, 100 mM NaCI, 0.5% gelatin, 0.1% Tween 20, 9.5% sucrose, and 0.02% NaN3.
100-200 Ml of sera or plasma were incubated for 30 min at room temperature with a 25-Ml suspension of microparticles (total surface area of 24-100 cm2) coated with monoclonal antibodies to HBsAg, pre-Sl region of HBsAg, pre-S2 region of HBsAg, or biotin obtained from Abbott Laboratories. The microparticles were pelleted in a microcentrifuge, washed once with PBS, suspended in water, heated, digested with proteinase K, and heated again as described above. The reaction mixture was centrifuged to pellet the microparticles. The supernatant was placed in another tube and PCR was performed as described. In some cases, the sera or plasma were centrifuged through a 0.9-ml spin column of Sephacryl 300 (Pharmacia Fine Chemicals, Piscataway, NJ) before adding the antibody-coated microparticles (9) .
Oligonucleotide primers were end-labeled by T4 polynucleotide kinase in a total volume of 15 Ml containing 15 mM Tris pH 7.4, 10 mM MgCI2, 0.1 mM EDTA, 0.1 spermidine, 5 mM DTT and 75Mm of gamma labeled [32P]dATP at 3,000 mCi per mM. The mixture was heated to 65°C for 10 min, then placed in ice for 2 min. 1 Ml (-5 U) of T4 polynucleotide kinase was added; reaction proceeded for 30 min at 37°C; heated for 65°C for 10 min; and then directly used for the hybridization. HBV DNA was nick translated as previously described (5).
DNA sequencing ofamplified DNA sequences After PCR, the reaction mixture was passed through a Sephadex G-50 spin column (9) , then sequenced by the dideoxy method of Sanger using the Taq DNA polymerase according to manufacturers' instruction (10 ,gl of serum; while monoclonal anti-HBs-coated microparticles detected 3 viruses. The yield of amplified DNA using monoclonal anti-HBs, anti-pre-S 1, and anti-pre-S2 coated microparticles was so great that ethidium bromide staining of the agarose gels was as sensitive as Southern blot analysis in detecting < 10 virus per serum specimen. While most serum specimens did not have to be diluted in PBS to improve the sensitivity of the assay, occasionally the intensity (yield) of the ethidium bromide amplified DNA fragment would increase if the sample were diluted in PBS. The yield of amplified DNA and the sensitivity of the assay improved if serum or plasma was first passed through a Sephacryl 300 spin column before adsorption to microparticles.
Amplified DNA could be directly sequenced by the dideoxy method of Sanger (10) . Using primers complementary to the s gene, a 690-bp fragment was amplified and sequenced from two HBV DNA positive sera, one of which lacked antiHBc antibody (Fig. 3) . The HBsAg of each sera was adw subtype. The HBV DNA concentration of the anti-HBc negative sera was -20,000 virus/ml at the lower limit of sensitivity ofa dot blot assay. While the other sera's amplified HBV DNA sequence was entirely identical to the published adw sequence (6), the anti-HBc negative sera was > 98% the same. When 690 bp - 45 sera that were obtained from healthy blood donors and that had normal ALT and negative serologies for HBV, HIV, and syphilis had no detectable amplified DNA using HBV specific oligonucleotide primers using either the Eppendorf tube or microparticle methods to adsorb virus before performing PCR. Rarely, negative control sera scored positive and the results of the entire experiment were discarded because of possible contamination of PCR reagents. More than 40 HBsAg+ sera were analyzed for HBV DNA by both dot blot and PCR. In every instance in which sera were positive by dot blot assay, PCR methodology using either the antibody-coated microparticle or Eppendorf tubes also produced a positive signal. Conversely, we identified HBsAg positive serum samples that were HBV DNA positive by PCR but negative by dot blot assay. "The s gene primers generated a DNA fragment that was 690 bp long. Anti-HBs coated microparticles were employed after passing 100,Ml sample through a 0.9-ml Sephacryl 300 spin column as described in Methods.
Discussion
Polymerase chain reaction is unable to be performed in serum because serum substances inhibit DNA polymerase activity. By adsorbing virus to a solid surface, washing the surface, then destroying the remaining proteins with proteinase K, we have found that PCR could detect serum HBV DNA at concentrations below the sensitivity of conventional dot blot and liquid hybridization assays. Desalting serum or plasma through a Sephacryl 300 spin column before adsorption also increased the sensitivity of the assay. A rough quantitation of viral DNA can be estimated by serially diluting a sample in HBV DNA negative serum or PBS. As little as three viruses per 200 ,l were detected using anti-HBs-, anti-pre-S The advantage of the method described above is that 100-200 ,ul of serum can be readily evaluated for the presence of HBV DNA with minimal manipulation. Depending on whether serum is diluted in PBS or serum and depending on the adsorptive surface (Eppendorf tubes vs. antibody-coated microparticles), the sensitivity of our method of performing PCR is -10-to 1,000-fold more sensitive than conventional hybridization assays. DNA dot hybridization assays are one dimensional. Serum samples that contain large quantities of chromosomal and other types of DNA are often falsely scored positive by dot blot assay due to nonspecific adsorption of probe. PCR on normal human chromosomal DNA with HBV DNA specific primers fail to produce positive signals, that is, a band at the exact molecular weight expected for the oligonucleotide primers used (data not shown). Thus PCR is both more sensitive and specific than liquid and dot blot hybridization assays. Despite published documentation that low concentrations of viral DNA may be detected by PCR after extraction and precipitation (3, 4), we have found that this method is at least 100-fold less sensitive as the antibody-coated microparticle technique (data not shown). Another advantage of the microparticle technique is that it is only able to detect virally encapsulated DNA since antibody-coated microparticles are used to capture the virion. Chromosomal DNA that sometimes is present in serum are not included in the PCR.
The sensitivity of PCR approaches the lower limit of infectivity of hepatitis B virus in chimpanzees. Since not all HBsAg positive patients are actively replicating virus but may have integrated viral DNA that act as transcripts for surface antigen (12) (13) (14) , it is theoretically possible that PCR analysis may distinguish infectious from noninfectious individuals. Reduction of this to clinical practice is not warranted since some patients may have episomal viral DNA that is not actively producing virions. These patients may be temporarily serum HBV DNA negative only to have reactivation of viral replication at a later time. Thus, despite the availability of a rapid and an extremely sensitive assay for serum HBV DNA, the absence of a viral DNA signal should not exclude the possibility that an HBsAg positive patient is no longer infectious for hepatitis B virus.
A major obstacle to the universal adoption of PCR for detecting serum HBV DNA is its extreme sensitivity. Miniscule contamination of samples or reagents with even a single DNA molecule can result in a false positive signal. We have, therefore, had to resort to handling specimens in different locations than the PCR reagents and using multiple negative and positive controls with each PCR trial. The data for a trial was discarded if any controls' results were false. In most instances, each serum sample was analyzed more than once at both neat Detection ofHepatitis B Virus DNA by Polymerase Chain Reaction 1507 and one-tenth dilution. In this way, we could be confident about the validity of our results.
The utility of PCR lies in the rapid and sensitive detection of HBV DNA sequences from small quantities of biological fluids and cells. We have previously described an infection model for HBV DNA using hemopoietic stem cells (18) . We are now able to assay these stem cells for the presence of HBV DNA as well as the production and secretion of small quantities of viral particles. Here we present data regarding the rapid isolation and sequencing of a segment of the s gene from a patient with abnormal hepatitis B virus serology (i.e., anti-HBc negative, HBsAg positive). Our microparticle methodology should allow the'sequencing of the entire HBV genome from such patients. Furthermore, this PCR method coupled with dideoxy sequencing should allow verification that cells are infected by viruses produced in HepG2 transformants modified by site specific mutagenesis.
In conclusion, we describe a method for detecting HBV DNA in serum by the polymerase chain reaction. An advantage of this method is that it can be performed on serum with minimal manipulation and without having to extract and precipitate nucleic acid. The ability to detect only a few HBV DNA molecules should allow a redefinition ofthe virology and course of hepatitis B infection. Direct PCR detection of viral nucleic acid by adsorption to a solid matrix should be applicable for the diagnosis of a variety of viremias.
